Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTEM: Eplerenone for subretinal fluid after ocriplasmin
NCT04300881Phase 2Terminated
- Sponsor
- Wagner Macula & Retina Center
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eplerenone in vitreomacular traction (VMT) and subretinal edema (2 arms), sponsored by Wagner Macula & Retina Center. Primary endpoint: Central Foveal Thickness at 52 weeks. Started Oct 2019; status: terminated.
02
Drugs
eplerenone
03
Conditions
vitreomacular traction (VMT)subretinal edema
Beyond the preview
Go deeper on NCT04300881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300881.